News
ALRN
3.850
-3.75%
-0.150
Weekly Report: what happened at ALRN last week (1028-1101)?
Weekly Report · 1d ago
Aileron Therapeutics’ ALRN-6924 to be acquired by Advancium Health Network
TipRanks · 5d ago
*Advancium Paid Aileron Non-Refundable Fee for Exclusive Option to Acquire ALRN-6924 and Related Assets >ALRN
Dow Jones · 5d ago
Aileron Therapeutics And Advancium Health Network Announced An Exclusive Option Agreement For The Acquisition Of ALRN-6924, Developed By Aileron Prior To Its 2023 Merger With Lung Therapeutics
Benzinga · 5d ago
*Advancium Will Evaluate ALRN-6924 as a Potential Therapy for Retinoblastoma
Dow Jones · 5d ago
*Aileron Therapeutics: Agreement Marks First of Its Kind for Advancium, a Public Charity Launched by Deerfield
Dow Jones · 5d ago
AILERON THERAPEUTICS AND ADVANCIUM HEALTH NETWORK ANNOUNCE AN EXCLUSIVE OPTION AGREEMENT FOR THE ACQUISITION OF ALRN-6924 FOR RETINOBLASTOMA
Reuters · 5d ago
Press Release: Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
Dow Jones · 5d ago
Weekly Report: what happened at ALRN last week (1021-1025)?
Weekly Report · 10/28 11:57
Weekly Report: what happened at ALRN last week (1014-1018)?
Weekly Report · 10/21 11:52
Weekly Report: what happened at ALRN last week (1007-1011)?
Weekly Report · 10/14 12:29
Reported Saturday, Aileron Therapeutics To Present Phase 1b Trial Data On LTI-03 For Idiopathic Pulmonary Fibrosis At 22nd Lung Fibrosis Colloquium
Benzinga · 10/14 07:27
Weekly Report: what happened at ALRN last week (0930-1004)?
Weekly Report · 10/07 12:16
Weekly Report: what happened at ALRN last week (0923-0927)?
Weekly Report · 09/30 12:06
Weekly Report: what happened at ALRN last week (0916-0920)?
Weekly Report · 09/23 12:05
Aileron Therapeutics Completes Enrollment for Phase 1b IPF Drug Trial, Topline Data Expected Soon
Benzinga · 09/23 11:37
AILERON THERAPEUTICS INC - COHORT 2 TO EVALUATE HIGH-DOSE LTI-03 (5 MG BID)
Reuters · 09/23 11:30
Weekly Report: what happened at ALRN last week (0909-0913)?
Weekly Report · 09/16 11:52
Weekly Report: what happened at ALRN last week (0902-0906)?
Weekly Report · 09/09 12:06
Weekly Report: what happened at ALRN last week (0826-0830)?
Weekly Report · 09/02 12:10
More
Webull provides a variety of real-time ALRN stock news. You can receive the latest news about Aileron Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ALRN
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. It has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.